Hitachi and Centre Léon Bérard have opened a research lab in Lyon that will apply AI to medical imaging and predict response to radiation therapy from genomic markers.
The consortium is comprised of researchers from Inova, Roswell Park Comprehensive Cancer Center, the Mayo Clinic, and MD Anderson Cancer Center.
The company released new data showing that Cologuard 2.0 can detect colorectal cancer with higher sensitivity than the current version of the test.
The companies plan to explore opportunities to use Thermo Fisher's LC-MS instrumentation to develop tools to determine the risk for adverse pregnancy outcomes.
Tempus is eligible for milestone payments and royalties for any oncology therapeutics Genmab might develop based on their joint research projects.
The German company's new Genome Enhancer product is an adaptation of its flagship multi-omics software for clinicians and biologists without bioinformatics expertise.
The companies will use Freenome's platform to identify cancer patients who are most likely to respond to treatment with ADC's loncastuximab tesirine.
Bioinformaticians at the Free University of Brussels have built a database, machine learning technology, and web platform for identifying elusive pathogenic gene pairs.
In a Phase II trial, Sophia will look for genomic markers of clinical response to ADC's treatment for relapsed or refractory diffuse large B-cell lymphoma.
University of Crete spinout Gnosis Data Analysis is adding AI capabilities to Indivumed's IndivuType multi-omics cancer research platform.
ScienceInsider reports that rude and unprofessional paper reviewers are common and can have harmful effects.
The US Senate has confirmed Stephen Hahn as the next commissioner of the Food and Drug Administration, according to the New York Times.
CNBC reports Apple is partnering with Color Genomics to offer its employees free DNA screening for disease.
In Science this week: researchers use CRISPR tool to find gut microbiome molecules involved in immunity, and more.